Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Clinical Pharmacology
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Clinical Pharmacology
    Escitalopram Decreases Symptoms of Major Depressive Disorder in Adolescents: Presented at AACAP - (DGDispatch)
    Cetuximab Continues to Increase Survival in Patients With Head and Neck Cancer for Up to 5 Years - (DGNews)
    Indacaterol Produces Effective Bronchodilation in Patients With COPD During 1 Year of Treatment: Presented at CHEST 2009 - (DGDispatch)
    FDA Approves Romidepsin Injection for Previously Treated T-Cell Lymphoma - (DGNews)
    Long-Term Treatment With Tiotropium Is Effective for Men, Women With COPD: Presented at CHEST 2009 - (DGDispatch)

    News archive

     Recent webcasts/CME - Clinical Pharmacology
    • Optimizing Insulin-Dependent Diabetes Management in Long-Term Care
    • Insulin-Dependent Diabetes in Long-Term Care: Scope of the Problem and Effective Management
    • Insulin-Dependent Diabetes in Long-Term Care: Practical Considerations
    • Patient-Centered Approaches to the Evaluation and Management of Atrial Fibrillation
      Optimizing Antihypertensive Therapy and Health and Economic Outcomes in a Managed Care Environment

      Webcasts/CME archive

       Recent cases - Clinical Pharmacology
        Rapid and Persistent Selection of the K103N Mutation as a Majority Quasispecies in a HIV1-Patient Exposed to Efavirenz for Three Weeks: A Case Report and Review of the Literature
        Reversible Cerebellar Syndrome Caused by Metronidazole
        Complete Remission of Severe Idiopathic Cold Urticaria on Interleukin-1 Receptor Antagonist (Anakinra)
        Rapid Resolution of Nitrofurantoin-Induced Interstitial Lung Disease
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report

        Cases archive
          




        my personal edition > clinical pharmacology > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Reboxetine and Citalopram Similar in Efficacy in Treatment of Panic Disorder

        A DGReview of :"Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study"
        International Clinical Psychopharmacology

        09/17/2003
        By Deanna M Green, PhD


        The selective serotonin reuptake inhibitor (SSRI) citalopram and the selective noradrenergic reuptake inhibitor (NRI) reboxetine are comparably effective and tolerable treatments for panic disorder, according to a preliminary South African study.

        Noradrenergic and serotonergic neurotransmitters are both involved in the pathophysiology of panic disorder. Therapeutic inhibitors of these pathways, known as the NRIs and SSRIs, respectively, are available and have shown promising results for the treatment of panic disorder. The comparative efficacy of these drugs, however, has had little study. It is also not known whether some patients respond better to one treatment as opposed to the other.

        Soraya Seedat and colleagues at the University of Stellenbosch, Cape Town, South Africa, conducted a pilot study to compare the safety and efficacy of reboxetine and citalopram in the treatment of patients with panic disorder.

        The single-blind, cross-over design study included 19 patients (8 men and 11 women, average age 36) with panic disorder. Patients were randomised to receive either reboxetine (4-10 mg/day) or citalopram (10 to 60 mg/day) for 8 weeks. Patients subsequently underwent a 2-week washout period and were then switched to the other drug regimen. Efficacy was assessed every 2 weeks throughout the course of the study.

        At end of 18 week study, 54% of patients responded to reboxetine and 82% responded to citalopram. Furthermore, one citalopram non-responder showed response to reboxetine; and conversely, 3 reboxetine non-responders showed response to citalopram. Notably, only 9 patients completed the entire study, yet 17 gave sufficient data for inclusion in analysis. Discontinuation was primarily due to transport and work-related problems.

        Overall, similar efficacy in general anxiety symptoms and disability were measured with both treatments. Significant improvement in panic attack severity was observed with both reboxetine and citalopram treatment. However, the study did find that patients showed a greater reduction in depressive symptoms while receiving citalopram.

        Regarding adverse events, citalopram was more often associated with nausea, decreased libido, increased yawning and loss of appetite; while patients undergoing reboxetine treatment reported a higher incidence of insomnia, sweating, constipation, dizziness/fainting, headache, and hot flashes. The most common side effect reported in both groups was dry mouth (58% with citalopram and 46% with reboxetine treatment).

        The authors conclude that "although SSRIs are viewed as a first-line treatment for panic disorder, these results suggest that a NA agent such as reboxetine may also have a role." They add that "these data also suggest an advantage for citalopram in treating comorbid depressive symptoms, although some patients may respond preferentially to an SSRI and other patients to an NRI."

        They also note "the findings of this study should be interpreted with caution in view of the small sample and the high non-completer rate."


        Int Clin Psychopharmacol 2003 Sep;18:5:279-84. "Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send